Next Article in Journal
Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines
Previous Article in Journal
Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue s1
10.3747/co.22.2363
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature

by
X. Zhu
and
S. Verma
*
Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(s1), 19-28; https://doi.org/10.3747/co.22.2363
Submission received: 12 December 2014 / Revised: 13 January 2015 / Accepted: 13 February 2015 / Published: 1 March 2015

Abstract

Breast tumours positive for HER2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond. The present review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer.
Keywords: her2; metastatic breast cancer; targeted therapy; phase iii trials her2; metastatic breast cancer; targeted therapy; phase iii trials

Share and Cite

MDPI and ACS Style

Zhu, X.; Verma, S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Curr. Oncol. 2015, 22, 19-28. https://doi.org/10.3747/co.22.2363

AMA Style

Zhu X, Verma S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Current Oncology. 2015; 22(s1):19-28. https://doi.org/10.3747/co.22.2363

Chicago/Turabian Style

Zhu, X., and S. Verma. 2015. "Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature" Current Oncology 22, no. s1: 19-28. https://doi.org/10.3747/co.22.2363

APA Style

Zhu, X., & Verma, S. (2015). Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Current Oncology, 22(s1), 19-28. https://doi.org/10.3747/co.22.2363

Article Metrics

Back to TopTop